Trial Profile
Pilot study of sorafenib for RET fusion positive non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Nov 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Mar 2012 New trial record